STENOCARE financing need has been completed as planned incl solution for refinancing of debt
STENOCARE confirms guidance and reports limited capital requirements ahead of the first TO1-warrant subscription starting on 6 December 2023
STENOCARE reports on significant progress in development of its new innovative medical cannabis product
STENOCARE A/S (“Stenocare”) delivered products to its 5 markets during Q4 2022 corresponding to net sales of 2.8 mDKK and is on track for its sales expectations for 2023 in the range of 15-20 mDKK
Investor Update: The first shipment of Stenocare medical cannabis oil products has arrived in Norway and the products are ready for patients.
Investor Update: Today, the new STENOCARE CBD medical cannabis oil product is available in Denmark. The first shipment has arrived, and sales of the product can begin.
Stenocare accesses the Norwegian market. Stenocare has signed a distribution agreement with the leading distributor and pharmacy chain.
STENOCARE and Emerald have been accepted by Swedish health authorities to offer patients’ treatment with medical cannabis oil